Skip to main content
NVDA+0.02%AAPL+0.11%GOOGL-3.15%MSFT-0.05%AMZN+0.11%TSM-4.52%SPCX-9.14%META-0.55%AVGO-4.31%TSLA-0.45%LLY+2.83%BRK-B+1.50%MU-1.37%WMT+2.82%SKHY-8.07%JPM+0.40%AMD-8.10%V+1.59%XOM+0.08%JNJ+3.81%ASMLa-4.74%MA+1.70%ABBV+0.03%INTC-8.04%COST+1.99%CVX-0.04%0700.HK+1.60%1398.HK-1.80%CSCO-2.21%KO+2.87%PG+5.58%UNH+1.91%ORCL-2.80%BAC+0.59%1816.HK-27.81%3988.HK-0.79%HD+4.33%CAT-4.89%0005.HK-0.49%PM+2.17%HSBA.L-2.45%0857.HK-0.52%GE-0.79%0939.HK+0.59%AP2d-6.79%1288.HK-1.60%AMAT-8.16%NVS+1.52%MS-1.63%LRCX-11.76%EURAUD-1.28%EURCAD-1.14%AUDUSD+1.05%EURNZD-0.94%USDCAD-0.91%USDTHB+0.87%AUDCHF+0.81%EURJPY-0.79%NZDUSD+0.73%EURGBP-0.69%CADCHF+0.67%USDJPY-0.59%GBPAUD-0.58%AUDJPY+0.51%NZDCHF+0.48%GBPUSD+0.47%GBPCAD-0.46%EURCHF-0.46%USDTRY+0.43%GBPTRY+0.41%CHFJPY-0.36%CADJPY+0.35%AUDNZD+0.34%GBPHKD+0.32%GBPMXN-0.28%GBPNZD-0.28%USDCHF-0.25%NOKJPY+0.25%CHFNOK-0.24%NZDSGD+0.24%EURUSD-0.23%GBPCHF+0.21%USDCNH-0.21%NZDCAD-0.19%CHFSEK-0.16%USDILS+0.16%SGDJPY+0.15%AUDCAD+0.15%CHFSGD-0.14%NZDJPY+0.14%NZDMXN+0.13%GBPJPY-0.11%USDHKD-0.10%USDPLN+0.10%PLNJPY+0.10%EURPLN+0.08%EURNOK-0.07%AUDNOK-0.05%USDSGD+0.05%USDMXN-0.05%AUDSGD+0.05%USDNOK-0.04%USDCOP-0.04%USDZAR+0.03%USDSEK+0.03%EURSGD+0.03%GBPZAR-0.03%EURCZK+0.03%EURCNH-0.02%EURHKD+0.02%USDDKK+0.02%EURZAR+0.02%AUDDKK+0.02%EURSEK+0.02%GBPSGD-0.01%EURDKK0.00%USOIL+1.63%UKOIL+1.12%GAGUSD-1.02%XAGUSD-1.02%HG1+0.98%XNGUSD-0.65%XPTUSD+0.34%W1+0.32%COTTON+0.26%XAUUSD-0.25%GAUUSD-0.25%S1+0.21%BTCUSD-2.66%ETHUSD+16.36%USDTUSD-0.07%XRPUSD+9.91%SOLUSD+10.75%TRXUSDT-0.20%ZECUSDT-6.76%DOGEUSD+14.39%XMRUSDT-1.95%LINKUSD+14.52%XLMUSD-2.94%BCHUSDT-0.31%UNIUSD-3.05%LTCUSD+8.69%SUIUSD-2.89%HBARUSDT-4.05%TONUSD+26.39%TAOUSDT-3.33%AAVEUSD-3.40%DOTUSDT+2.82%ICPUSDT-3.90%WLDUSDT-5.15%ONDOUSDT-4.89%ARBUSDT-2.98%JUPUSDT-4.25%ATOMUSDT+2.74%INJUSDT-4.87%STXUSDT-10.02%TIAUSDT-7.07%FETUSDT-3.34%PYTHUSDT-7.72%SEIUSDT-6.05%IMXUSDT-5.35%GRTUSDT-2.96%OPUSDT-7.20%WIFUSDT-4.61%IOTAUSDT-2.94%AXSUSDT-3.65%POLUSDT-2.90%FARTCOINUSDT-2.16%EOSUSDT-1.29%DYDXUSDT-3.74%GALAUSDT-2.52%ORDIUSDT-0.99%RONINUSDT-1.83%NOTUSDT-2.47%NVDA+0.02%AAPL+0.11%GOOGL-3.15%MSFT-0.05%AMZN+0.11%TSM-4.52%SPCX-9.14%META-0.55%AVGO-4.31%TSLA-0.45%LLY+2.83%BRK-B+1.50%MU-1.37%WMT+2.82%SKHY-8.07%JPM+0.40%AMD-8.10%V+1.59%XOM+0.08%JNJ+3.81%ASMLa-4.74%MA+1.70%ABBV+0.03%INTC-8.04%COST+1.99%CVX-0.04%0700.HK+1.60%1398.HK-1.80%CSCO-2.21%KO+2.87%PG+5.58%UNH+1.91%ORCL-2.80%BAC+0.59%1816.HK-27.81%3988.HK-0.79%HD+4.33%CAT-4.89%0005.HK-0.49%PM+2.17%HSBA.L-2.45%0857.HK-0.52%GE-0.79%0939.HK+0.59%AP2d-6.79%1288.HK-1.60%AMAT-8.16%NVS+1.52%MS-1.63%LRCX-11.76%EURAUD-1.28%EURCAD-1.14%AUDUSD+1.05%EURNZD-0.94%USDCAD-0.91%USDTHB+0.87%AUDCHF+0.81%EURJPY-0.79%NZDUSD+0.73%EURGBP-0.69%CADCHF+0.67%USDJPY-0.59%GBPAUD-0.58%AUDJPY+0.51%NZDCHF+0.48%GBPUSD+0.47%GBPCAD-0.46%EURCHF-0.46%USDTRY+0.43%GBPTRY+0.41%CHFJPY-0.36%CADJPY+0.35%AUDNZD+0.34%GBPHKD+0.32%GBPMXN-0.28%GBPNZD-0.28%USDCHF-0.25%NOKJPY+0.25%CHFNOK-0.24%NZDSGD+0.24%EURUSD-0.23%GBPCHF+0.21%USDCNH-0.21%NZDCAD-0.19%CHFSEK-0.16%USDILS+0.16%SGDJPY+0.15%AUDCAD+0.15%CHFSGD-0.14%NZDJPY+0.14%NZDMXN+0.13%GBPJPY-0.11%USDHKD-0.10%USDPLN+0.10%PLNJPY+0.10%EURPLN+0.08%EURNOK-0.07%AUDNOK-0.05%USDSGD+0.05%USDMXN-0.05%AUDSGD+0.05%USDNOK-0.04%USDCOP-0.04%USDZAR+0.03%USDSEK+0.03%EURSGD+0.03%GBPZAR-0.03%EURCZK+0.03%EURCNH-0.02%EURHKD+0.02%USDDKK+0.02%EURZAR+0.02%AUDDKK+0.02%EURSEK+0.02%GBPSGD-0.01%EURDKK0.00%USOIL+1.63%UKOIL+1.12%GAGUSD-1.02%XAGUSD-1.02%HG1+0.98%XNGUSD-0.65%XPTUSD+0.34%W1+0.32%COTTON+0.26%XAUUSD-0.25%GAUUSD-0.25%S1+0.21%BTCUSD-2.66%ETHUSD+16.36%USDTUSD-0.07%XRPUSD+9.91%SOLUSD+10.75%TRXUSDT-0.20%ZECUSDT-6.76%DOGEUSD+14.39%XMRUSDT-1.95%LINKUSD+14.52%XLMUSD-2.94%BCHUSDT-0.31%UNIUSD-3.05%LTCUSD+8.69%SUIUSD-2.89%HBARUSDT-4.05%TONUSD+26.39%TAOUSDT-3.33%AAVEUSD-3.40%DOTUSDT+2.82%ICPUSDT-3.90%WLDUSDT-5.15%ONDOUSDT-4.89%ARBUSDT-2.98%JUPUSDT-4.25%ATOMUSDT+2.74%INJUSDT-4.87%STXUSDT-10.02%TIAUSDT-7.07%FETUSDT-3.34%PYTHUSDT-7.72%SEIUSDT-6.05%IMXUSDT-5.35%GRTUSDT-2.96%OPUSDT-7.20%WIFUSDT-4.61%IOTAUSDT-2.94%AXSUSDT-3.65%POLUSDT-2.90%FARTCOINUSDT-2.16%EOSUSDT-1.29%DYDXUSDT-3.74%GALAUSDT-2.52%ORDIUSDT-0.99%RONINUSDT-1.83%NOTUSDT-2.47%
ST

Sarepta Therapeutics, Inc. (SRPT)

NASDAQ • Healthcare

$18.18
-$0.37 (-2.0%)
Market closed

Last close at October 22, 2026 at 20:00 UTC

Open$18.4
Day Range$18.11 - $18.94
Avg. Volume (3M)2.9M
Market Cap$1.9B
52 Week Range
$14.68$24.68

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$401.2M100%
Gross Profitminus cost of goods$251.8M63%
Operating Incomeminus R&D and overhead$13.2M3%

In plain terms: out of every $100 in revenue, Sarepta Therapeutics, Inc. currently loses $1.

Fundamentals & Financials

Revenue (TTM)
$1.9B
Net Income (TTM)
-$136.7M
EPS (TTM)
-$1.44
ROA (TTM)
-4.29%
Current Ratio
4.42

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-247.6%Q1 2026-$3.58
+223.8%Q2 2026$3.16
-123.0%Q3 2026-$0.05

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -123.0%

Sarepta Therapeutics beat consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported Aug. 5, based on preliminary results. Revenue came in at about $401.3 million, down 34% from $611.1 million a year ago but about 10% above the $366.4 million estimate, while adjusted EPS was $0.64 versus $0.22 expected, about +195%, even as it fell 68% from $2.02 a year earlier. Gross profit reached about $251.9 million, and the 62.8% gross margin left operating margin near 3% as operating income landed at about $13.3 million. Operating cash flow was negative about $5.6 million.

Next report — what to expect

Sarepta Therapeutics, Inc. (SRPT) is set to report earnings on November 4, 2026. Wall Street’s next-period consensus calls for EPS of $0.136 on revenue of $353.8 million. For trailing context, revenue fell -34.3% year over year last quarter. Sarepta has beaten EPS in 4 of 8 most recent quarters.

View full earnings history

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. develops genetic medicines for rare diseases and operates in biotechnology within the healthcare sector. Listed on NASDAQ as SRPT, the company combines commercial Duchenne muscular dystrophy therapies with a broader pipeline of RNA-targeted therapeutics and gene therapies, generating $2.2 billion of revenue in FY2025.

Name
Sarepta Therapeutics, Inc.
CEO
Michael E. Severino
Website
www.sarepta.com
Industry
Healthcare
Year Founded
1980
Employees
835

Today's Snapshot

AI-generated

SRPT closed 2% lower at 18.18, against a firmer sector. Volume was about a third of its usual level. Sarepta scheduled its third-quarter financial results for Nov. 5.

Trading Volume

Below 10d avg (3.6M)

1.2M

vs S&P 500 Today

Underperforming Market

-0.79%

Updated: October 22, 2026 at 20:27 UTC

Technical Indicators

2 Buy3 Neutral3 Sell
SRPT presents a mixed, neutral technical profile with price hovering between short-term moving averages and longer-term resistance, producing conflicted signals. Momentum indicators are largely flat and MACD is slightly negative while RSI is near center, and ADX under sixteen indicates a lack of directional conviction. Volatility is elevated with an ATR around a dollar and OBV suggests recent distribution, while pivot levels lie just above the current price. Taken together these elements offer no clear edge. Technical takeaway: Neutral — indicators and volume are mixed with a weak trend and little directional conviction.
All signals
  • EMA (5 indicators)$18.00 - $19.18
    Sell
  • RSI (14)49.10
    Neutral
  • Stochastic %K (14, 3, 3)68.07
    Neutral
  • MACD Level (12, 26)-0.30
    Neutral

Peers & Related Assets

ALNYAlnylam Pharmaceuticals, Inc.
$227.28+1.0%
IONSIonis Pharmaceuticals, Inc.
$43.91-0.8%
PTCTPTC Therapeutics, Inc.
$63.04+0.7%
DYNDyne Therapeutics, Inc.
$15.77-1.9%
NTLAIntellia Therapeutics, Inc.
$11.16-4.2%
SLDBSolid Biosciences Inc.
$6.19-3.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.